Hepatitis News : Many Nutritional Supplements Make False Claims
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » October 2012


emailprint

October 4, 2012

Many Nutritional Supplements Make False Claims

Dozens of over-the-counter health supplements, including some potentially used by people living with HIV, viral hepatitis and other chronic diseases, are illegally labeled and lack scientific evidence for their marketed claims, according to a report released October 2 by the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services.

Label Claim
Some supplements claim to prevent, treat or cure diseases.
Source: Office of Inspector General
The report stems from an analysis of both the structure and function claims of 127 dietary supplements marketed for weight loss or immune system support. OIG reviewed the claims to determine the extent to which they complied with FDA regulations, along with substantiation provided by manufacturers to describe the quantity and nature of the evidence. Investigators also assessed the accuracy and completeness of notification letters that manufacturers must submit to FDA for their structure/function claims.

Overall, substantiation documents for the supplements were inconsistent with FDA requirements for competent and reliable scientific evidence. Additionally, the report notes, seven percent of the supplements lacked the required disclaimer pertaining to unproven health benefits and 20 percent included prohibited disease claims on their labels.

In light of these findings, OIG recommends that the U.S. Food and Drug Administration (FDA) “seek explicit statutory authority to review substantiation for structure/function claims to determine whether they are truthful and not misleading.” The OIG investigators also recommend “that FDA improve the notification system for these claims to make it more organized, complete, and accurate,” adding that the agency should “expand market surveillance to enforce the use of disclaimers for structure/function claims and to detect disease claims.”

In commenting on the report, the FDA did not explicitly concur with OIG’s first recommendation, but said it would consider it. It did, however, concur with OIG’s second and third recommendations.

To read the OIG report, click here.

Search: supplements, alternative, therapies, hiv, hepatitis, wellness, health, weight loss, immune system, department of health and human services, hhs, food and drug administration, fda, report


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (3 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.